Relay Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
RLAY$19.94-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statem ents of Cash Flows
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities: | |||
| Net loss | $(337,708) | $(341,973) | $(290,509) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation expense | 5,464 | 5,269 | 4,130 |
| Stock compensation expense | 94,139 | 86,031 | 56,138 |
| Net realized gain on sale of investments | (101) | — | — |
| Net amortization of premiums and discounts on investments | (12,315) | (10,763) | 1,182 |
| Change in fair value of contingent consideration liability | (13,206) | (6,422) | (11,677) |
| Changes in assets and liabilities: | |||
| Accounts receivable | — | 306 | 97 |
| Contract asset | — | 4,913 | (376) |
| Prepaid expenses and other current assets | (5,356) | (4,648) | (2,140) |
| Operating lease assets and liabilities, net | 1,243 | 1,509 | (8,132) |
| Accounts payable and accrued expenses | 10,268 | (9,590) | 11,289 |
| Deferred revenue | 7,679 | — | (248) |
| Other liabilities | 786 | (24,948) | 10,756 |
| Net cash used in operating activities | (249,107) | (300,316) | (229,490) |
| Cash flows from investing activities: | |||
| Purchases of property and equipment | (2,018) | (4,126) | (9,062) |
| Purchases of investments | (650,629) | (385,542) | (535,419) |
| Proceeds from maturities and sales of investments | 611,564 | 647,302 | 355,736 |
| Net cash provided by (used in) investing activities | (41,083) | 257,634 | (188,745) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock through Private Placement, net | 29,803 | — | — |
| Proceeds from issuance of common stock via at-the-market offerings, net | 17,932 | 30,281 | — |
| Proceeds from issuance of common stock through follow-on offering, net | 218,157 | — | 284,744 |
| Proceeds from issuance of common stock through exercise of stock options | 2,782 | 1,986 | 3,480 |
| Proceeds from issuance of common stock via employee stock purchase plan | 1,479 | 2,486 | 1,686 |
| Net cash provided by financing activities | 270,153 | 34,753 | 289,910 |
| Net decrease in cash, cash equivalents, and restricted cash | (20,037) | (7,929) | (128,325) |
| Cash, cash equivalents, and restricted cash at beginning of period | 146,443 | 154,372 | 282,697 |
| Cash, cash equivalents, and restricted cash at end of period | $126,406 | $146,443 | $154,372 |
| Supplemental disclosure of non-cash activities: | |||
| Periodic change in additions of property and equipment within current liabilities | $(1,544) | $410 | $159 |
| Periodic change in costs to obtain license agreement within current liabilities | $2,508 | $— | $— |
| Operating lease assets obtained in exchange for operating lease liabilities | $— | $— | $46,626 |
| Issuance of common stock upon milestone achievement | $— | $12,750 | $6,203 |
Reconciliation of Cash, Cash Equivalents, and Restricted Cash from Balance Sheets to Statements of Cash Flows
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| (in thousands) | ||
| Cash and cash equivalents | $124,287 | $143,736 |
| Restricted cash | 2,119 | 2,707 |
| Cash, cash equivalents, and restricted cash per statements of cash flows | $126,406 | $146,443 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.